STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net loss	$ (52,371)	$ (42,856)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	61	32
Stock-based compensation expense	6,145	3,061
Amortization of premiums and accretion of discounts on marketable securities, net	(3,121)	487
Change in fair value of embedded derivatives	1,360	0
Amortization of right-of-use asset	123	137
Non-cash research and development expense	739	0
Realized gain on marketable securities	(11)	0
Non-cash interest expense	145	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(369)	1,700
Other assets	(70)	(137)
Accounts payable	(261)	552
Accrued clinical trial expenses	1,670	2,570
Accrued expenses and other current liabilities	2,989	(562)
Finance lease liability	17	0
Operating lease liability	(110)	(137)
Net cash used in operating activities	(43,064)	(35,153)
Cash flows from investing activities
Purchases of marketable securities	(250,634)	(41,514)
Proceeds from maturities and sales of marketable securities	78,981	80,860
Proceeds from sale of property and equipment	3	0
Purchases of property and equipment	(21)	(161)
Net cash provided by (used in) investing activities	(171,671)	39,185
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	121,904	3,792
Proceeds from Term Loan	30,000	0
Payments for financing costs	(476)	0
Proceeds from exercise of stock options	325	115
Net cash provided by financing activities	151,753	3,907
Net change in cash and cash equivalents and restricted cash	(62,982)	7,939
Cash and cash equivalents and restricted cash at the beginning of the period	130,101	122,162
Cash and cash equivalents and restricted cash at the end of the period	67,119	130,101
Supplemental disclosure of cash flow information
Cash paid for income taxes	0	0
Cash paid for interest	169	0
Supplemental disclosure of noncash financing activities
Right-of-use assets obtained in exchange for finance lease liabilities	739	0
Right-of-use assets obtained in exchange for operating lease liabilities	399	242
Issuance of warrant with Term Loan	$ 1,132	$ 0